Company / Gross Profit
AVADEL PHARMACEUTICALS PLC Gross Profit History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$153.8M
FY2024
5-year range
$0 / $153.8M
FY2021-FY2024
Trend
+467.3%
vs FY2023
Sector context
#23 of 29
Health Care
What the data says
AVADEL PHARMACEUTICALS PLC's gross profit of $154M is lower than 79% of companies in the Health Care sector (FY2024). Improved from $0 to $154M over the past 2 years.
Based on SEC 10-K filings.
$154M in FY2024.
Improved from $0 to $154M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 29This company $153.8M Sector average $3.5B
▼
-95.6% below sector average
Key checks
Key Insights
- In FY2024, gross profit increased 467.3% year-over-year.
- Ranks #23 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $153.8M | +467.3% |
| FY2023 | $27.1M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026